Velez v. Microgenics Corporation

CourtDistrict Court, W.D. New York
DecidedJuly 16, 2020
Docket1:20-cv-00387
StatusUnknown

This text of Velez v. Microgenics Corporation (Velez v. Microgenics Corporation) is published on Counsel Stack Legal Research, covering District Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Velez v. Microgenics Corporation, (W.D.N.Y. 2020).

Opinion

SEs □□□ UNITED STATES DISTRICT COURT y JUL 16 2020 WESTERN DISTRICT OF NEW YORK Lean OO LTE CARLOS VELEZ, Plaintiff, v. 20-CV-387 (JLS) (JJM) MICROGENICS CORPORATION and THERMO FISHER SCIENTIFIC, INC., Defendants.

DECISION AND ORDER Pro se plaintiff Carlos Velez is in Department of Corrections and Community Supervision (“DOCCS”) custody at Five Points Correctional Facility. He filed a complaint, seeking relief under this Court’s diversity jurisdiction, for violation of his rights when DOCCS disciplined him for drug use while he was confined at Attica Correctional Facility (“Attica”). Dkt. 1. Specifically, Velez seeks relief because the testing equipment Defendants provided to DOCCS produced a false positive result. See id. Velez also requested permission to proceed in forma pauperis. Dkt. 2. Defendant Microgenics Corporation appeared and moved to dismiss. Dkt. 4. For the reasons discussed below, Velez’s claims will be dismissed pursuant to 28 U.S.C. § 1915(e)(2)(B)—and Microgenics’s motion to dismiss denied as moot—unless Velez files an amended complaint as directed.

DISCUSSION Because Velez satisfied the statutory requirements of 28 U.S.C. § 1915(a) and filed the required authorization (Dkt. 2), he is granted permission to proceed in forma pauperis. Therefore, under Section 1915(e)(2)(B), this Court must screen Velez’s complaint. Section 1915 “provide[s] an efficient means by which a court can screen for and dismiss legally insufficient claims.” Abbas v. Dixon, 480 F.3d 636, 639 (2d Cir. 2007) (citing Shakur v. Selsky, 391 F.3d 106, 112 (2d Cir. 2004)). The Court shall dismiss a complaint in a civil action in which a prisoner seeks redress from a governmental entity, or an officer or employee of a governmental entity, if the Court determines that the action: (1) fails to state a claim upon which relief may be granted; or (2) seeks monetary relief against a defendant who is immune from such relief. See 28 U.S.C. §§ 1915A(b)(1)-(2). And the Court shall dismiss the complaint of a civil litigant proceeding pro se if, among other reasons, the complaint “fails to state a claim on which relief may be granted.” See 28 U.S.C. § 1915(e)(2)(B)Gi). Generally, the Court will afford a pro se plaintiff an opportunity to amend or to be heard before dismissal “unless the court can rule out any possibility, however unlikely it might be, that an amended complaint would succeed in stating a claim.” Abbas, 480 F.3d at 639 Gnternal quotations omitted). But leave to amend may be denied when any amendment would be futile. See Cuoco v. Moritsugu, 222 F.3d 99, 112 (2d Cir. 2000).

I. Review of the Complaint. The Court must accept all factual allegations as true and must draw all inferences in Velez’s favor when evaluating the complaint. See Larkin v. Savage, 318 F.3d 138, 139 (2d Cir. 2003) (per curiam); King v. Simpson, 189 F.3d 284, 287 (2d Cir. 1999). “Specific facts are not necessary,” and a plaintiff “need only ‘give the defendant fair notice of what the .. . claim is and the grounds upon which it rests.” Erickson v. Pardus, 551 U.S. 89, 93 (2007) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (internal quotations and citation omitted)); see also Boykin v. Keycorp, 521 F.3d 202, 216 (2d Cir. 2008) (“[E]ven after Twombly, dismissal of a pro se claim as insufficiently pleaded is appropriate only in the most unsustainable of cases.’). A court “is obliged to construe [pro se] pleadings liberally, particularly when they allege civil rights violations,” McKachin v. McGuinnis, 357 F.3d 197, 200 (2d Cir. 2004), but even pro se pleadings must meet the notice requirements of Rule 8 of the Federal Rules of Civil Procedure, see Wynder v. McMahon, 360 F.3d 73, 79 n.11 (2d Cir. 2004). Under these standards, Velez alleges that, while confined at Attica in June 2019, he submitted a urine sample that was tested with the “Indiko Plus urinalysis analyzer.” See Dkt. 1, at 4] 20. The urine sample Velez submitted returned a “false positive” for prohibited drug use. As a result, Velez was subjected to thirty days in keeplock, lost attendant privileges, and lost opportunities like preferential transfer to a prison closer to home as disciplinary sanctions. See id. at 1 4; id. at 2 J] 5-6. On January 6, 2020, “DOCCS confirmed that... Velez’s test

results were a faulty false positive.” Id. at 5 § 24. Velez alleges that Defendants! were negligent in providing the equipment to DOCCS, in training DOCCS officers on the equipment, in operating and maintaining the equipment, and in failing to ensure that equipment at DOCCS facilities functioned properly. See Dkt. 1, at 5 26. II. Analysis of Velez’s Claims. As explained above, the Court must dismiss the complaint if it determines that the complaint fails to state a claim for relief. See 28 U.S.C. § 1915(e)(2)(B)(ii). Neither defendant has been formally served. Nevertheless, Defendant Microgenics moved to dismiss the complaint. See Dkt. 4. Defendant Thermo Fisher Scientific, Inc. has not responded to the complaint, so the complaint is subject to initial Section 1915 review. Because the Court dismisses the complaint with leave to amend, as set forth below, it denies Microgenics’s motion to dismiss as moot. See Graham v. Bank of Am., 482 F. App’x 41 (2d Cir. 2011) (addressing sua sponte dismissal and holding that “a district court must dismiss an action when ... the complaint fails to state a claim on which relief may be granted,” citing 28 U.S.C. § 1915(e)(2)(B)ay).

1 Thermo Fisher, including Fisher Scientific, “manufactures in vitro diagnostic reagents, calibrators, and controls,” and Microgenics “specializes in developing, validating, manufacturing, and supplying drugs for abuse testing... and therapeutic drug monitoring... assays.” Fisher Sct. Co. L.L.C. v Ortho-Clinical Diagnostics, Inc., No. 1:18-CV-3088 (ALC), 2019 WL 1427564, at *1 (S.D.N.Y. Mar. 29, 2019).

A. Negligence Claims Against Defendants. Velez raises negligence claims against Defendants, based on this Court’s diversity jurisdiction. See Dkt. 1, at 6 § 28-7 935.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Boykin v. KeyCorp
521 F.3d 202 (Second Circuit, 2008)
Coppedge v. United States
369 U.S. 438 (Supreme Court, 1962)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Peranzo v. Coughlin
675 F. Supp. 102 (S.D. New York, 1987)
United States v. Macardell Dobbins
482 F. App'x 35 (Sixth Circuit, 2012)
Landon v. Kroll Laboratory Specialists, Inc.
999 N.E.2d 1121 (New York Court of Appeals, 2013)
Davidson v. Flynn
32 F.3d 27 (Second Circuit, 1994)
Cuoco v. Moritsugu
222 F.3d 99 (Second Circuit, 2000)
Shakur v. Selsky
391 F.3d 106 (Second Circuit, 2004)
Abbas v. Dixon
480 F.3d 636 (Second Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
Velez v. Microgenics Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/velez-v-microgenics-corporation-nywd-2020.